Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial

Background: Liposomal cisplatin is a new formulation developed to reduce the systemic toxicity of cisplatin while simultaneously improving the targeting of the drug to the primary tumor and to metastases by increasing circulation time in the body fluids and tissues. The primary objectives were to de...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Stathopoulos, G. P., Antoniou, D., Dimitroulis, J., Michalopoulou, P., Bastas, A., Marosis, K., Stathopoulos, J., Provata, A., Yiamboudakis, P., Veldekis, D., Lolis, N., Georgatou, N., Toubis, M., Pappas, Ch., Tsoukalas, G.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2010
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2962260/
https://ncbi.nlm.nih.gov/pubmed/20439345
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdq234
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky